{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-011122","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.386305+00:00","generated_at":"2026-06-26T21:28:42.353659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022","bullets":["Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.","FY2021 net loss $70.8M ($2.45/share); Q4 net loss $18.9M ($0.35/share).","GPH101 Phase 1/2 CEDAR trial: first patient dosing now H2 2022 (COVID-19 impact); initial data 2023.","New programs: GPH102 for beta-thalassemia (IND mid-2024) and early AAT deficiency program.","Appointed Alethia Young as CFO, Christine Garrett as Chief of Staff/SVP Ops; promoted Julia Tran to CPO."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-011122","json":"https://secwatch.observer/filing/0001564590-22-011122.json","markdown":"https://secwatch.observer/filing/0001564590-22-011122.md","text":"https://secwatch.observer/filing/0001564590-22-011122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/0001564590-22-011122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/grph-8k_20220321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:28:42.353659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}